Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

被引：0
|
作者：
Yinzhu Jin
Rishi J. Desai
Jun Liu
Nam-Kyong Choi
Seoyoung C. Kim
机构：
[1] Brigham and Women’s Hospital,Division of Pharmacoepidemiology and Pharmacoeconomics
[2] Institute of Environmental Medicine,Department of Health Convergence
[3] Medical Research Center,Division of Rheumatology, Immunology and Allergy
[4] Seoul National University,undefined
[5] Ewha Womans University,undefined
[6] Brigham and Women’s Hospital,undefined
来源：
Arthritis Research & Therapy | / 19卷
关键词：
Rheumatoid arthritis; Antirheumatic agents; Biologic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
    Jin, Yinzhu
    Desai, Rishi J.
    Liu, Jun
    Choi, Nam-Kyong
    Kim, Seoyoung C.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [2] Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis
    Jin, Yinzhu
    Desai, Rishi J.
    Liu, Jun
    Choi, Nam-Kyong
    Kim, Seoyoung
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    Hosseini, Roya
    Fawaz, Souhiela
    Seoane-Vazquez, Enrique
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2595 - 2595
  • [4] FACTORS ASSOCIATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS UTILIZATION IN RHEUMATOID ARTHRITIS PATIENTS
    Hosseini, R.
    Brown, L.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S453 - S453
  • [5] FACTORS ASSOCIATED WITH INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hammou, O.
    Chennouf, F.
    Azzouzi, H.
    Linda, I.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1441 - 1441
  • [6] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [7] Factors Associated with the Initiation of Biologic Disease-Modifying Antirheumatic Drugs in Texas Medicaid Patients with Rheumatoid Arthritis
    Kim, Gilwan
    Barner, Jamie C.
    Rascati, Karen
    Richards, Kristin
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (05): : 401 - 407
  • [8] Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia
    Machado-Alba, J. E.
    Ruiz, A. F.
    Machado-Duque, M. E.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (06) : 506 - 511
  • [9] Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis
    Desai, Rishi J.
    Hansen, Richard A.
    Rao, Jaya K.
    Wilkins, Tania M.
    Harden, Elizabeth A.
    Yuen, Andrea
    Jonas, Daniel E.
    Roubey, Robert
    Jonas, Beth
    Gartlehner, Gerald
    Lux, Linda
    Donahue, Katrina E.
    [J]. ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1491 - 1505
  • [10] Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis
    Schiff, MH
    Whelton, A
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2000, 30 (03) : 196 - 208
12345